Oncology

Latest News

Analyzed by birth cohort, the authors found each successive birth cohort had a 7.7% decline in SCLC rates. | Image credit: shidlovski
Decline in SCLC Incidence Expected to Accelerate Through 2050

June 29th 2025

The incidence of small cell lung cancer (SCLC) is projected to drop by 5.9% each year through 2050.

While elevated NLR previously served as a marker of aggressive disease and poor prognosis in SCLC, its prognostic relevance appears to diminish in the context of immunotherapy-based treatment regimens. | Image credit: Crystal light - stock.adobe.com
Challenging the Prognostic Role of NLR in SCLC in the Era of Immunotherapy

June 27th 2025

Gender rights | Image Credit: © Nadzeya-stock.adobe.com
Culture Key to Data Collection of Sexual Orientation and Gender Identity in Cancer Care

June 23rd 2025

AJMC Q&A with Coral Omene, MD, PhD | Background image credit: ipopba - stock.adobe.com
Addressing Cancer Care Challenges for Patients, and Ensuring Equity: Coral Omene, MD, PhD

June 22nd 2025

Patients with SCLC in the tarlatamab group had significantly longer overall survival, with a median of 13.6 months vs 8.3 months in the chemotherapy group. | Image credit: mi_viri - stock.adobe.com
Tarlatamab Improves SCLC Outcomes After Platinum Chemotherapy

June 19th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations
Continuing Medical Education
View All
June 30th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
June 30th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Chemotharapy graphic-tashatuvango-stock.adobe.com.jpeg
September 23rd 2024

Higher Risk of Heart Events in Older Cancer Survivors Linked to Chemotherapy

Pearl Steinzor
New research highlights increased stroke, heart attack, and heart failure risks in cancer survivors, especially those treated with chemotherapy.
Glenn Balasky during a video interview
September 22nd 2024

AI in Cancer Care Can Be Powerful, but There Will Be Learning Curves, Says Glenn Balasky

Alexandra Gerlach Laura Joszt, MA
Demonstration projects to show accurate use of artificial intelligence (AI) in cancer care are important to prevent a loss of credibility in the technology, explained Glenn Balasky, executive director, Rocky Mountain Cancer Centers.
dr joseph alvarnas
September 22nd 2024

Precision, Personalization, and Equity: Key Trends Shaping the Future of Cancer Care

Brooke McCormick
Joseph Alvarnas, MD, of City of Hope, discusses how he envisions the future of cancer care over the next decade.
dr joseph alvarnas
September 20th 2024

IVBM Chair Summarizes Key Takeaways on Value-Based Oncology Care

Brooke McCormick
Joseph Alvarnas, MD, of City of Hope, recaps yesterday's Institute for Value-Based Medicine® (IVBM) event on value-based oncology care, emphasizing patient-centered approaches and how attendees can apply these insights in their daily practice.
AJMC
September 20th 2024

Systemic Treatments for Advanced Prostate Cancer: Relationship Between Health Insurance Plan and Treatment Costs

Deborah R. Kaye, MD, MS Hui-Jie Lee, PhD Alexander Gordee, MA Daniel J. George, MD Charles D. Scales Jr, MD, MSHS Peter A. Ubel, MD M. Kate Bundorf, PhD, MBA, MPH
The authors examine how insurer and patient out-of-pocket payments for advanced prostate cancer differ by drug and health plan type and describe the relationship between these payments and utilization.
Incorporating Discussions of Cannabis Use Into Oncology Care Visits
September 15th 2024

Incorporating Discussions of Cannabis Use Into Oncology Care Visits

Laura Joszt, MA
The legalization of recreational marijuana in Minnesota has created daily conversations about how to incorporate the use of cannabis into treatment plans for patients with cancer, explained Marie Parish, PharmD, BCOP, of Mayo Clinic.
Cancer health care concept-wladimir1804-stock.adobe.com
September 13th 2024

From Policy to Practice: NCCN Summit Explores Equity in the Cancer Workforce

Giuliana Grossi
The National Comprehensive Cancer Network Policy Summit emphasized the importance of integrating diversity, equity, and inclusion into the oncology workforce to improve cancer care outcomes and address disparities while navigating legal and societal challenges.
Addressing Disparities in Long-Term Survivorship and Quality of Life for Young Patients With Breast Cancer
September 13th 2024

Addressing Disparities in Long-Term Survivorship and Quality of Life for Young Patients With Breast Cancer

Alana Hippensteele
Disparities continue in younger patients, raising the need for novel interventions to mitigate challenges associated with younger age at diagnosis.
Dax Kurbegov, MD, senior vice president, Sarah Cannon Cancer Network
September 12th 2024

Dr Dax Kurbegov on Gaps Between Payers, Health Systems, and Providers in Oncology

Rose McNulty
Dax Kurbegov, MD, senior vice president of Sarah Cannon Cancer Network, discussed divides between payers, health systems, and oncology care providers, as well as the impacts these divides can have on patients.
Brain MRI | Image credit: stockdevil - stock.adobe.com
September 11th 2024

TIM3 Targeted Immunotherapy Shows Promise in Pediatric Brain Cancer

Pearl Steinzor
Breakthrough research identifies TIM3 as a key target in MAPK-activated pediatric gliomas, offering new hope for more effective immunotherapy treatments.
AJMC
September 6th 2024

The Feasibility and Equity of Text Messaging to Determine Patient Eligibility for Lung Cancer Screening

Ilona Fridman, PhD Lisa Carter-Bawa, PhD, MPH, APRN, ANP-C Christine M. Neslund-Dudas, PhD Jennifer Elston Lafata, PhD
Text messaging shows promise for assessing smoking status and identifying lung cancer screening eligibility, particularly among middle-aged, educated individuals with medium or high income. However, a multimodal approach is crucial for equitable implementation of such a program.
Doctor and patient with breast cancer. | Image Credit: Pixel-Shot - stock.adobe.com .jpeg
September 3rd 2024

The Connection Between Cancer Treatment Choices and Suicide Mortality

Pearl Steinzor
Patients with cancer who forego surgery have higher suicide incidence than those who undergo treatment, a study finds.
When to Pause Before Recommending Cannabis to Patients With Cancer
September 1st 2024

When to Pause Before Recommending Cannabis to Patients With Cancer

Laura Joszt, MA
Despite lacking some data, there is some information on which patients with cancer shouldn’t be recommended cannabis or certain cannabis products, said Marie Parish, PharmD, BCOP, a gastrointestinal oncology pharmacist with Mayo Clinic.
Matthew Nielsen, MD
August 31st 2024

Using Active Surveillance to Spare Men From Unneeded Prostate Cancer Treatment

Laura Joszt, MA
Advances in technology have made active surveillance in men with prostate cancer possible and prevented treatment for men who don’t need it, said Matthew Nielsen, MD, FACS, chair, Department of Urology, University of North Carolina School of Medicine.
Neal D. Shore, MD
August 28th 2024

Evaluating Which Patients With Prostate Cancer Will Benefit From Triplet Therapy

Laura Joszt, MA
Not all patients will want to take triplet therapy, but those with high-volume prostate cancer who are chemotherapy eligible are usually a good fit, explained Neal D. Shore, MD, FACS.
Value-based care concept | Image credit: momius - stock.adobe.com
August 27th 2024

Thyme Care Strengthens Value-Based Oncology Care With Dr Lalan Wilfong

Pearl Steinzor
Thyme Care welcomes its new senior vice president to lead initiatives in value-based oncology care.
Health care concept on $100 dollar bill | Image credit: ricardoreitmeyer - stock.adobe.com
August 26th 2024

The Role of Community, Structural Factors in Financial Hardship Among Cancer Survivors

Pearl Steinzor
Social vulnerability and economic disadvantages exacerbate financial hardship in cancer survivors, according to one study.
Marie Parish, PharmD, BCOP, screenshot
August 22nd 2024

Using Cannabis as a Bridge for Symptom Management in Cancer

Laura Joszt, MA
Patients with cancer will never completely replace existing pain regimens, but cannabis could be used in conjunction, explained Marie Parish, PharmD, BCOP, a gastrointestinal oncology pharmacist with Mayo Clinic.
Psychologist holding arm of patient in support | Image credit: pressmaster - stock.adobe.com
August 21st 2024

Spouses of Patients With Cancer Face Elevated Suicide Risk, Study Finds

Pearl Steinzor
Spouses of patients with cancer face a significantly higher risk of suicide attempts and suicide death, especially within the first year of diagnosis, according to one study.
FDA approval | Image Credit: cartoon-stock.adobe.com
August 16th 2024

FDA Approves Durvalumab Combination Therapy for Resectable Early-Stage NSCLC

Pearl Steinzor
The newly approved treatment regimen demonstrated a significant reduction in recurrence risk in patients with resectable non–small cell lung cancer (NSCLC).
Andrew Hantel, MD
August 14th 2024

We Need to Lower Barriers to and Burdens of Trial Entry: Dr Andrew Hantel

Kyle Munz
Andrew Hantel, MD, Dana-Farber Cancer Institute, discusses factors contributing to disparities in oncology clinical trial enrollment.
AJMC
August 13th 2024

The Accelerated Approval Program for Oncology Drugs: Celebrating More Than 250,000 Life-Years Gained and Counting

Julie Patterson, PharmD, PhD John Michael O’Brien, PharmD, MPH Jonathan D. Campbell, PhD
This commentary explores how 2 recently published studies evaluating the clinical benefit of the FDA’s accelerated approval program for oncology drugs came to different conclusions.
FDA Approved
August 8th 2024

FDA Approves Denileukin Difitox for Refractory Cutaneous T-Cell Lymphoma

Julia Bonavitacola
Relapsed or refractory cutaneous t-cell lymphoma can be treated in adults with the new FDA approval of denileukin diftitox immunotherapy.
Brain tumor 3D illustration | Imaged credit: Dr_Microbe - stock.adobe.com
August 7th 2024

Vorasidenib Approved by FDA for Grade 2 IDH-Mutant Glioma

Pearl Steinzor
Vorasidenib becomes the first targeted therapy for grade 2 isocitrate dehydrogenase (IDH)–mutant glioma to receive FDA approval.
Medical mammogram exam | Image Credit: TeraVector - stock.adobe.com
August 6th 2024

COVID-19 Disrupted Breast Cancer Screenings, Exacerbated Disparities

Cameron Santoro
The COVID-19 pandemic disrupted breast cancer screenings, leading to decreased follow-up rates and widening health disparities.
3D illustration of ovarian cancer | Image Credit: Lars Neumann - stock.adobe.com
August 6th 2024

Patients With Endometriosis May Have Higher Ovarian Cancer Risk

Brooke McCormick
Patients with endometriosis have a 4.2-fold greater ovarian cancer risk, highlighting the need for further research into the biological links between endometriosis subtypes and ovarian cancer.
Lung cancer diagnosis | Image Credit: Vitalii Vodolazskyi-stock.adobe.com
August 1st 2024

NSCLC Study Highlights Need for Adjuvant Trials in Early-Stage Disease

Maggie L. Shaw
Visceral pleural invasion of non–small cell lung cancer (NSCLC) was investigated in this analysis for its potential to predispose patients to worse survival outcomes and greater chances of disease recurrence.
Amit Singal, MD, UT Southwestern Medical Center
August 1st 2024

Addressing Ongoing Disparities in Liver Cancer Care: Dr Amit Singal

Rose McNulty
Amit Singal, MD, medical director of the Liver Tumor Program and chief of hepatology at UT Southwestern Medical Center, discusses his research on disparities in hepatocellular carcinoma care in the US.
Pink ribbon for breast cancer. | Image Credit: Andrey Popov - stock.adobe.com
July 31st 2024

Black Women With Obesity, Elevated Leptin Levels at Higher Risk for Breast Cancer

Cameron Santoro
The risk of early-onset breast cancer, particularly luminal A and triple-negative subtypes, was higher in Black women with obesity and high leptin levels compared with White women. This research highlights the urgent need for targeted interventions to address racial disparities in breast cancer outcomes.
cancer patient enjoying life | Image credit: VadimGuzhva - stock.adobe.com
July 29th 2024

Protein Signatures Could Improve Patient Outcome Predictions in Soft Tissue Sarcomas

Skylar Jeremias
A study demonstrates the value of incorporating protein signatures in creating more advanced prediction tools for patient outcomes.
<1
...
34567891011
...
186>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo